MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Gossamer Bio Inc

Chiusa

SettoreSettore sanitario

1.45 -4.61

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.42

Massimo

1.52

Metriche Chiave

By Trading Economics

Entrata

-3.6M

-37M

Vendite

510K

9.9M

Margine di Profitto

-370.492

Dipendenti

144

EBITDA

-1.9M

-34M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+543.38% upside

Dividendi

By Dow Jones

Utili prossimi

8 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

34M

284M

Apertura precedente

6.06

Chiusura precedente

1.45

Notizie sul Sentiment di mercato

By Acuity

84%

16%

353 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Gossamer Bio Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 lug 2025, 22:07 UTC

I principali Market Mover

Trade Desk Rises on S&P 500 Inclusion

14 lug 2025, 17:06 UTC

I principali Market Mover

Crypto Assets Rally Ahead of Possible U.S. Legislation

14 lug 2025, 16:47 UTC

Acquisizioni, Fusioni, Takeovers

NatWest to Sell Stake in Permanent TSB

14 lug 2025, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise as Yen Weakens -- Market Talk

14 lug 2025, 23:38 UTC

Discorsi di Mercato

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14 lug 2025, 23:37 UTC

Discorsi di Mercato

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14 lug 2025, 23:29 UTC

Discorsi di Mercato

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14 lug 2025, 23:29 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

14 lug 2025, 23:02 UTC

Utili

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14 lug 2025, 23:02 UTC

Utili

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14 lug 2025, 23:02 UTC

Utili

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14 lug 2025, 23:01 UTC

Utili

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14 lug 2025, 23:01 UTC

Utili

China Vanke Expects 1H Loss to Widen >000002.SZ

14 lug 2025, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

14 lug 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

14 lug 2025, 20:07 UTC

Discorsi di Mercato

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14 lug 2025, 20:05 UTC

Discorsi di Mercato

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14 lug 2025, 19:11 UTC

Discorsi di Mercato

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14 lug 2025, 19:09 UTC

Discorsi di Mercato

Gold Breaks a 3-Day Win Streak -- Market Talk

14 lug 2025, 18:59 UTC

Discorsi di Mercato

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14 lug 2025, 18:30 UTC

Acquisizioni, Fusioni, Takeovers

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14 lug 2025, 18:25 UTC

Discorsi di Mercato

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14 lug 2025, 18:25 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

14 lug 2025, 16:59 UTC

Discorsi di Mercato

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14 lug 2025, 16:53 UTC

Azioni calde

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14 lug 2025, 16:27 UTC

Discorsi di Mercato

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14 lug 2025, 16:20 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

14 lug 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

14 lug 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

14 lug 2025, 16:12 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Confronto tra pari

Modifica del prezzo

Gossamer Bio Inc Previsione

Obiettivo di Prezzo

By TipRanks

543.38% in crescita

Previsioni per 12 mesi

Media 8.75 USD  543.38%

Alto 15 USD

Basso 4 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Gossamer Bio Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

5

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.06 / 1.23Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

353 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.